To summarize promising areas of investigation in osteoporosis and to stimulate further
research in this area, as discussed in a recent international conference. Over the recent …

Animal models are fundamental to advance our knowledge of the underlying
pathophysiology of bone loss and to study pharmaceutical countermeasures against it. The …

Abstract Purpose of Review This review summarizes recently published data and other
developments around osteoanabolic osteoporosis therapies in patients with very high …

Guidelines for osteoporosis treatment are available; however, these guidelines suggest
when to treat patients, without specific recommendations on what drugs to prescribe in …

Antiresorptive therapies are used to increase bone strength in individuals with osteoporosis
and include five principal classes of agents: bisphosphonates, estrogens, selective estrogen …

Osteoporosis is an enormous and growing public health problem. Once considered an
inevitable consequence of ageing, it is now eminently preventable and treatable. Ironically …

Background Previous bisphosphonate treatment attenuates the bone-forming effect of
teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin …

Romosozumab (Evenity®), a humanized monoclonal antibody, promotes bone formation
and inhibits bone resorption by inhibiting sclerostin, a protein involved in the regulation of …

Worldwide, there are millions of people who have been diagnosed with osteoporosis, a
bone disease that increases the risk of fracture due to low bone mineral density and …

Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by
increasing bone formation and reducing bone resorption, and thus has favorable effects in …